Delivers daunorubicin and cytarabine to bone marrow at a fixed molar ratio1

VYXEOS is the first dual-drug liposomal encapsulation that has been shown to deliver daunorubicin and cytarabine at a fixed molar ratio over a prolonged period of time1-4

  • The 1:5 molar ratio of daunorubicin and cytarabine was shown to be synergistic in killing leukemia cells in vitro and in murine models1
  • This ratio was shown to be maintained in the plasma for up to 24 hours in a Phase 1 clinical trial4

VYXEOS: Mechanism of Action

Key highlights for the VYXEOS mechanism of action

Based on animal studies…

  • Delivery to bone marrow

    Delivery to bone marrow1

    VYXEOS liposomes enter and persist in the bone marrow

  • Leukemia cell uptake

    Leukemia cell uptake1

    The liposomes are taken up by leukemia cells to a greater extent than by normal bone marrow cells in a murine model

  • Release of daunorubicin and cytarabine

    Release of daunorubicin and cytarabine1

    VYXEOS liposomes undergo degradation, releasing daunorubicin and cytarabine within the intracellular environment